drugset

drugset / Trial / NCT05918692

A Phase 1 Study of BMF-500 in Adults With Acute Leukemia

NCT05918692 ↗

Phase 1 Active not recruiting 35 enrolled Biomea Fusion Inc.

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia.

Timeline

Start: 2023-07-26
Primary completion: 2026-04
Completion: 2026-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMF-500	Unknown	—	Oral

Indications